IDTA Quote, Financials, Valuation and Earnings

InspireMD has a net margin of 27.9% compared to IDenta's net margin of -435.91%. IDenta's return on equity of 79.65% beat InspireMD's return on equity of -68.55%.

IDenta has a consensus price target of --, signalling downside risk potential of --. On the other hand InspireMD has an analysts' consensus of -- which suggests that it could grow by 66.08%. Given that InspireMD has higher upside potential than IDenta, analysts believe InspireMD is more attractive than IDenta.

IDenta has a beta of 2.567, which suggesting that the stock is 156.741% more volatile than S&P 500. In comparison InspireMD has a beta of 0.985, suggesting its less volatile than the S&P 500 by 1.474%.

IDenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InspireMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDenta pays -- of its earnings as a dividend. InspireMD pays out -- of its earnings as a dividend.

IDenta quarterly revenues are $366.9K, which are smaller than InspireMD quarterly revenues of $1.8M. IDenta's net income of $102.3K is higher than InspireMD's net income of -$7.9M. Notably, IDenta's price-to-earnings ratio is 3.98x while InspireMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDenta is 1.31x versus 15.95x for InspireMD. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of 27.9% compared to IDenta's net margin of --. IDenta's return on equity of 79.65% beat BiomX's return on equity of --.

IDenta has a consensus price target of --, signalling downside risk potential of --. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1187.48%. Given that BiomX has higher upside potential than IDenta, analysts believe BiomX is more attractive than IDenta.

IDenta has a beta of 2.567, which suggesting that the stock is 156.741% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

IDenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDenta pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

IDenta quarterly revenues are $366.9K, which are larger than BiomX quarterly revenues of --. IDenta's net income of $102.3K is lower than BiomX's net income of $9.6M. Notably, IDenta's price-to-earnings ratio is 3.98x while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDenta is 1.31x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of 27.9% compared to IDenta's net margin of -1804.3%. IDenta's return on equity of 79.65% beat Pluri's return on equity of -438.78%.

IDenta has a consensus price target of --, signalling downside risk potential of --. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 619.1%. Given that Pluri has higher upside potential than IDenta, analysts believe Pluri is more attractive than IDenta.

IDenta has a beta of 2.567, which suggesting that the stock is 156.741% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.

IDenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDenta pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

IDenta quarterly revenues are $366.9K, which are larger than Pluri quarterly revenues of $326K. IDenta's net income of $102.3K is higher than Pluri's net income of -$5.9M. Notably, IDenta's price-to-earnings ratio is 3.98x while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDenta is 1.31x versus 39.53x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.

Raphael Pharmaceutical has a net margin of 27.9% compared to IDenta's net margin of --. IDenta's return on equity of 79.65% beat Raphael Pharmaceutical's return on equity of --.

IDenta has a consensus price target of --, signalling downside risk potential of --. On the other hand Raphael Pharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that IDenta has higher upside potential than Raphael Pharmaceutical, analysts believe IDenta is more attractive than Raphael Pharmaceutical.

IDenta has a beta of 2.567, which suggesting that the stock is 156.741% more volatile than S&P 500. In comparison Raphael Pharmaceutical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

IDenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDenta pays -- of its earnings as a dividend. Raphael Pharmaceutical pays out -- of its earnings as a dividend.

IDenta quarterly revenues are $366.9K, which are larger than Raphael Pharmaceutical quarterly revenues of --. IDenta's net income of $102.3K is higher than Raphael Pharmaceutical's net income of -$326K. Notably, IDenta's price-to-earnings ratio is 3.98x while Raphael Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDenta is 1.31x versus -- for Raphael Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.